Esteva FJ et al. |
What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? |
2015 |
Am Soc Clin Oncol Educ Book |
pmid:25993162
|
Martin M and López-Tarruella S |
Emerging Therapeutic Options for HER2-Positive Breast Cancer. |
2016 |
Am Soc Clin Oncol Educ Book |
pmid:27249772
|
Thigpen JT et al. |
Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. |
1983 |
Am. J. Clin. Oncol. |
pmid:6846245
|
Thigpen JT et al. |
Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. |
1983 |
Am. J. Clin. Oncol. |
pmid:6869315
|
Borden EC et al. |
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. |
1982 |
Am. J. Clin. Oncol. |
pmid:6956236
|
Slavik M et al. |
Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience. |
1982 |
Am. J. Clin. Oncol. |
pmid:6897490
|
Ravry MJ et al. |
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. |
1985 |
Am. J. Clin. Oncol. |
pmid:3834790
|
Fleming MS et al. |
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. |
2005 |
Anal. Biochem. |
pmid:15840500
|
Luo Q et al. |
Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. |
2016 |
Anal. Chem. |
pmid:26629796
|
Sang H et al. |
Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. |
2017 |
Anal. Chim. Acta |
pmid:28088282
|